40+ years of excellence in custom synthesis and bioconjugation services.
Calculators, design tools, and educational content to support your research.
Custom lipid architectures beyond conventional fatty acid, sterol and phospholipid conjugation. Bio-Synthesis supports feasibility-driven development of terminal, internal, nucleoside-associated, branched and multivalent lipid-modified DNA and RNA constructs while protecting project-specific and proprietary chemistry.
A lipid-modified oligonucleotide is a broad category. A nucleolipid more specifically describes an integrated amphiphilic architecture in which lipid character is engineered through a nucleoside, nucleotide, nucleobase, sugar or related molecular scaffold. Specialty lipid constructs may also use dual-chain anchors, branched hydrophobes, internal lipid positions or custom amphiphilic building blocks.
Projects may require 5′, 3′ or selected internal placement rather than a conventional terminal lipid conjugate.
Dual-chain, branched and multivalent designs can present hydrophobic groups from a defined scaffold.
Specialty phosphoramidites, activated derivatives and customer-supplied materials can be evaluated case by case.
Terminology: not every fatty-acid-conjugated oligonucleotide should be called a nucleolipid. This page focuses on specialty or structurally integrated lipid architectures extending beyond the major lipid classes covered on our dedicated pages.
For specialty projects, architecture is often more useful than a long catalog of individual compounds.
Introduce lipid functionality at a selected internal or nucleoside-associated position when terminal placement does not meet the experimental design.
Internal / nucleoside-associated
Specialty building block or conjugation
Sequence context and functional compatibility
Rather than publishing proprietary structures as standard products, representative specialty lipids are grouped by architecture. Availability and incorporation route depend on the actual functionalized material and project requirements.
Single- or dual-chain hydrophobic anchors based on ether or alkyl architectures.
Two hydrophobic chains presented through one molecular scaffold.
Functionalized glycerol-based amphiphiles outside standard phospholipid products.
Specialty sphingolipid-derived or inspired structures may be considered when suitable chemistry is available.
Carbohydrate–lipid amphiphilic architectures for specialty presentation and recognition studies.
Lipid functionality integrated through a nucleoside, nucleobase, sugar or related synthetic building block.
Architectures incorporating a cleavable or stimulus-responsive connection.
Novel activated lipids or amphiphiles can be reviewed without public listing as standard modifications.
Feasibility principle: availability of an activated material alone does not guarantee successful incorporation. Chemical stability, solubility, oligonucleotide compatibility, attachment position, purification behavior and analytical requirements must be considered together.
Membrane anchoring, self-assembly, uptake, protein association, delivery or surface display.
Single-chain, dual-chain, nucleolipid, branched, multivalent or cleavable.
5′, 3′, internal, nucleoside-associated or scaffold-defined placement.
Direct, alkyl, TEG, PEG or custom spacing.
Direct synthesis, specialty phosphoramidite, post-synthetic conjugation or custom intermediate.
Plan purification, analytical and handling strategies for hydrophobic constructs.
Some custom lipid modification projects involve project-specific or proprietary synthetic strategies. Exact structures, attachment chemistry and synthetic details do not need to be presented as public catalog products for feasibility evaluation.
Lipid functionality may be evaluated at selected internal, nucleoside-associated, sugar-associated or scaffold-defined positions.
Submit a structure or functionalized derivative for confidential feasibility assessment rather than relying on a fixed public list.
Attachment site, linker, chemistry, purification and analytics can be developed around the final architecture.
IP-conscious capability: certain specialty lipid architectures use proprietary or project-specific synthetic strategies and are therefore evaluated individually rather than disclosed as standard catalog modifications.
These references provide background on amphiphilic oligonucleotides, lipid–DNA/RNA conjugates, membrane anchoring, nucleolipid architectures, and hydrophobic oligonucleotide modification. They support design principles rather than defining a single manufacturing route.
Review literature describing how hydrophobic modification can influence self-assembly, membrane association, delivery, and supramolecular behavior of nucleic acids.
Search PubMed →
Literature on nucleoside–lipid and nucleotide–lipid amphiphiles provides background for structurally integrated nucleolipid building blocks and self-assembling systems.
Published work on lipidated DNA and RNA illustrates how single- and dual-chain hydrophobic anchors can be used for membrane insertion, vesicle association, and nanoscale assembly.
Scientific note: exact lipid structures, attachment positions, and synthetic routes vary widely across the literature. Published examples should be used as design precedent, not as a guarantee that every reported architecture is directly transferable to a specific oligonucleotide sequence or scale.
Share the lipid or amphiphile structure, oligonucleotide sequence, desired attachment position, available reactive functionality, scale, purification target, and analytical requirements. Bio-Synthesis can evaluate whether the project is best approached through a specialty phosphoramidite, activated derivative, post-synthetic conjugation, customer-supplied material, or project-specific development route.
Lipid: structure, MW, purity, reactive group Oligo: sequence, DNA/RNA format, modifications Position: 5′, 3′, internal, nucleoside-associated, scaffold-defined Project: scale, purification, analytical requirements
Novel lipid structures and proprietary architectures can be reviewed as project-specific feasibility requests without being published as standard catalog modifications.
Trusted by biotech leaders worldwide for over 45 years of delivering high-quality, fast, and scalable synthetic biology solutions.